GlaxoSmithKline (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2023

  1. Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain

    Infectious Diseases and Therapy, Vol. 12, Núm. 1, pp. 157-175

2012

  1. Five-year antibody persistence and safety following a booster dose of combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine

    Pediatric Infectious Disease Journal, Vol. 31, Núm. 10, pp. 1074-1077

2011

  1. Combined haemophilus influenzae type B-neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines

    Pediatric Infectious Disease Journal, Vol. 30, Núm. 11

2008

  1. Immunogenicity and reactogenicity of a booster dose of a novel combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age

    Pediatric Infectious Disease Journal, Vol. 27, Núm. 7, pp. 579-588

2007

  1. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months

    Pediatric Infectious Disease Journal, Vol. 26, Núm. 1, pp. 1-7